Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings

Creative Commons License

Gungor B., Yagci F. C. , GÜRSEL İ., GÜRSEL M.

ONCOIMMUNOLOGY, vol.3, no.7, 2014 (Peer-Reviewed Journal) identifier

  • Publication Type: Article / Editorial Material
  • Volume: 3 Issue: 7
  • Publication Date: 2014
  • Doi Number: 10.4161/21624011.2014.950166
  • Journal Name: ONCOIMMUNOLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus


Type I interferon inducers may potentially be engineered to function as antiviral and anticancer agents, or alternatively, vaccine adjuvants, all of which may have clinical applications. We recently described a simple strategy to convert a Toll-like receptor 9 (TLR9) agonist devoid of interferon alpha (IFN alpha) stimulating activity into a robust Type I interferon inducer with potent vaccine adjuvant activity.